• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT launches Sinuva steroid-releasing sinus implant

April 2, 2018 By Sarah Faulkner

Intersect ENTIntersect ENT (NSDQ:XENT) launched its steroid-releasing sinus implant, Sinuva, in the U.S. today. The company’s drug-eluting device is designed to treat nasal polyp disease in patients who have undergone previous sinus surgery.

Sinuva is placed during a routine doctor’s office visit and releases an anti-inflammatory steroid, mometasone furoate, directly to the patient’s nasal polyps for up to 90 days.

Intersect ENT estimates that nearly 635,000 Americans have undergone surgery to remove nasal polyps and ultimately have to return to their ENT physicians due to recurring symptoms.

“After years of development and multiple clinical studies, we are thrilled to provide physicians with Sinuva to treat patients with nasal polyps. Sinuva offers an alternative to patients who have exhausted routine medical management who don’t want to return to the operating room for a repeat surgery,” president & CEO Lisa Earnhardt said in prepared remarks. “We are introducing Sinuva through a targeted launch, working to build success through positive initial adoption and positioning Sinuva for the long-term growth we believe is achievable.”

In a 300-patient pivotal trial, participants treated with Sinuva had a statistically significant reduction in bilateral polyp grade from baseline to 90 days and a signification reduce in nasal obstruction score after 30 days. The drug-device combo won FDA approval in December last year.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Implants, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS